FDA accepts Teva-MedinCell’s new drug application for schizophrenia drug
The application is supported by data from two Phase III clinical trials of TV46000 in schizophrenia patients aged 13 to…
mental health conditions
Latest in
mental health conditions
Maternal smoking as potential risk factor for Tourette syndrome among children
Data from recent studies reinforce the evidence that suggests maternal smoking during pregnancy is a risk factor for Tourette syndrome.
By
FDA approves Alkermes’ Lybalvi for schizophrenia treatment
FDA has granted approval for Alkermes’ Lybalvi for treating schizophrenia in adults and helping with bipolar I disorder.
Major depressive disorder: why does it affect women more?
Major depressive disorder (MDD) is a common mental health disorder that affects more than 264 million people globally, and it…
By
Novartis to acquire neuroscience firm Cadent Therapeutics for up to $770m
Novartis has entered into a definitive agreement to acquire all of the outstanding capital stock of US-based neuroscience company Cadent…
Biogen and Sage Therapeutics to co-develop depression and tremor therapies
Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor…
Twitter round-up: Neurology tweets – David Perlmutter’s tweet on meditation most popular in December 2019
Pharmaceutical Technology lists ten of the most popular tweets on neurology in December 2019, based on data from GlobalData’s Influencer…
By
Psilocybin moves closer to becoming a licensed treatment for depression
The main psychoactive component in magic mushrooms, psilocybin, has passed its first clinical safety trial. The drug is now closer…
By